The clearance allows the bone void filler to be used with NuVasive’s procedurally integrated thoracolumbar interbody portfolio, NuVasive stated in a news release. Attrax Putty is a synthetic, bioactive and osteoconductive bone void filler designed to enable bone formation without added cells or growth factors.
This indication makes the bone void filler the first synthetic biologic cleared for use in interbody fusions of the thoracolumbar spine. It’s also supported by a level 1 trial for use in posterolateral spinal fusions.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
